An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Clinical trial NCT04950764 · COMPLETED

Trial details

NCT number: NCT04950764
Sponsor: Gilead Sciences
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Primary Biliary Cholangitis Compensated Cirrhosis Hepatic Impairment

Start date: 2021-11-16
Primary completion: 2025-02-24
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.